2015 CONFERENCE


 

Scientific programme

 
Sunday, 12 October
Scottish Exhibition and Conference Centre
Lomond Auditorium

Conference Co-Chairs
Greg Bousteaud, MD
Laurence Klotz, MD

WELCOME & INTRODUCTIONS

07:45Chairman's Welcome & Framing of Theme
 Laurence Klotz, MD | Canada
 
SESSION ONE | LOCALIZED PROSTATE CANCER
 Co-Moderators: Hashim Ahmed & Bertrand Tombal
 
07:55International Perspectives on Prostate Cancer Screening
 Yoshiyuki Kakehi, MD | Japan
 
08:10Have Molecular Markers Changed the Management of Localized Prostate Cancer?
 Peter Carroll, MD | USA
 
08:25Role of Statins, Metformin and Exercise in Prostate Cancer Prevention
 Matthew Cooperberg, MD | USA
 
08:40DISCUSSION
 
08:50How to Measure Effectiveness of Focal Therapy
 Philipp Dahm, MD | USA
 
09:05Focal Therapy! The New Snake Oil Medicine
 Over treatment for Indolent Disease & Under treatment for Aggressive Disease
 Henk van der Poel, MD | Netherlands
 
09:20Focal Therapy - Where is it Headed?
 Mark Emberton, MD | England
 
09:35DISCUSSION
 
SESSION TWO | PROSTATE CANCER
 Co-Moderators: Greg Boustead & Nathan Lawrentscuk
 
09:45Rationale for Metformin in Prostate Cancer
 Neil Fleshner, MD | Canada
 
10:00Template Versus Targeted Biopsy
 Hashim Ahmed, MD | England
 
10:15MRI imaging
 Arnaud Villers, MD | France
 
10:30DISCUSSION
 
10:40Da Vinci Robot for the Developing World: A Wasteful Trend or a Worthwhile Technology?
 Peter Hammerer, MD | Germany
 
10:50The Non-Western World Should Embrace the Robot
 Shin Egawa, MD | Japan
 
11:00Robotics - A Skeptical View from the Developing World
 Arturo Mendoza-Valdés, MD | Mexico
 
11:10DISCUSSION
 
11:20Intermittent ADT
  Bertrand Tombal | Belgium
 
11:35Management of Biochemical Failure - Role of Surgical Resection
  Hendrik Van Poppel, MD | Belgium
 
11:50DISCUSSION
 
SESSION THREE | A CLINICAL CASE IN PROSTATE CANCER
 Co-Moderators: Roger Kirby & Laurence Klotz
 
12:00International Perspectives on Clinical Management of Prostate Cancer
 Four (5 minute) clinical case presentations justifying each approach followed by a 15 minute open discussion
 CASE: 61 year old healthy man with PSA 20, Gleason 8 T2b prostate cancer
 PRESENTATIONS:
 Mack Roach, MD | USA (5 min):
 Mahesh Desai, MD | India (5min):
 Axel Heidenriech, MD | Germany (5 min):
 Scott Eggener, MD | USA (5 min):
 
12:20DISCUSSION
 
12:35BREAK & LUNCH SERVICE:
 (All Attendees: pick up lunch and return to seats for Session Four Working Lunch Session)
 
SESSION FOUR | A PROVOCATIVE DISCUSSION
 Co-Moderators: Roger Kirby & Laurence Klotz
 
13:00MAJOR OBSERVATIONS:
 Objectives: Four Key Opinion Leaders will identify the single most major observation in their field within the last 3 years. Each presenter will have 4 minutes to describe their observation, 4 minutes to put this into context and 4 minutes to receive comments by the Critique Panel. Critique Panel: Manfred Wirth, Philipp Dahm, Thomas Keane, -
 
Observation #1: Gerry Andriole (Prostate)
 Observation #2: Christian Steif (Prostate)
 Observation #3: Peter Mulders (Kidney)
 Observation #4: Sharokh Shariat (Upper Tract Urothelial Carcinoma)
 
SESSION FIVE | BLADDER CANCER
 Moderator: Laurence Klotz
 
13:50POLAND: Bladder Cancer Prevention Update
 Roman Sosnowski, MD | Poland
 
14:00ITALY: Bladder Cancer Prevention Update
 Maurizio Brausi, MD | Italy
 
14:10Enhanced Bladder Tumor Visualization Techniques:
 Are They Worth It and Do They Have a Role?
 Theo de Reijke, MD | Netherlands
 
14:20DISCUSSION
 
SESSION SIX | RENAL CANCER
 Moderators: R.Houston Thompson & Ofer Yossepowitch
 
14:25Partial Nephrectomy in the Elderly: Is it worth the increased risk of complications?
 Bradley Leibovich, MD | USA
 
14:35Focal Therapy for Renal Cancer
 Damien Bolton, MD | Australia
 
14:45Lessons from the Nephrectomy Outcomes Data
 Adrian Joyce, MD | England
 
14:55The Role of lymph node dissection in RCC
 Christopher Wood, MD | USA
 
15:05DISCUSSION
 
SESSION SEVEN | DEBATE: TESTOSTERONE REPLACEMENT | Fool’s Paradise or Elixir of Youth?
 Moderator: Peter Hammerer
 
15:10Argument For | Testosterone Replacement is Safe
 Larry Goldenberg, MD | Canada
 
15:20Argument Against | Safety is Unproven
 Laurence Klotz, MD | Canada
 
15:30DISCUSSION
 
15:45Adjourn
 Laurence Klotz, MD | Canada
 
 
© World Urologic Oncology Federation (WUOF)